| Name | Title | Contact Details |
|---|---|---|
Ari Benderly |
Chief Information Security Officer | Profile |
P/Kaufmann is a prominent textile company founded in New York City in 1957. It is recognized as one of the largest producers of decorative and woven fabrics, primarily serving the home and hospitality markets. The company has a strong reputation for design excellence and quality, with a diverse range of products that include rich solids, contemporary geometrics, florals, and exotic ikats. Their fabrics are suitable for upholstery, drapery, and various home décor applications. The company operates multiple divisions, including Braemore, which focuses on upscale designs, and Folia, which offers licensed fabrics and wallcoverings for Ralph Lauren Home. P/Kaufmann Contract caters specifically to the hospitality sector, providing a refined identity and marketing system for the design trade. They also offer innovative tools, such as an online color picker, to assist designers in matching fabric swatches. P/Kaufmann serves a global clientele, including interior designers and hospitality businesses, delivering high-quality decorative textiles and comprehensive support services.
Weve run the gambit on virtually everything you can do with an automobile. From donuts at Tire Slayer Studios to gravity-defying stunts on the streets of Las Vegas, weve earned our stripes on the automotive front lines, the pits, and the winners podium. Its a sense of pride and passion that allows us to continue to push the boundaries that make us who we are. At our core, we are enthusiasts just like our customers. We connect with our fans in a way most brands cant imagine. Because at one time, we, too, were just enthusiasts pursuing our passion for automotive culture and watching our motorsport heroes from the grandstands.
Reef Aquaria Design (RAD) is committed to creating custom sustainable, living aquarium ecosystems.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.